Veracyte Inc (VCYT)

$38.08 -0.66 (-1.70%)
Market Cap 3.06B
Revenue (ttm) 445.76M
Net Income (ttm) 24.14M
EPS (ttm) N/A
PE Ratio 34.67
Forward PE 32.20
Profit Margin 5.42%
Debt to Equity Ratio 0.00
Volume 1,213,100
Avg Vol 839,532
Day's Range N/A - N/A
Shares Out 79.05M
Stochastic %K 9%
Beta 1.88
Analysts Strong Sell
Price Target $48.20

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 650 243 6300
Fax: 650 243 6388
Address:
6000 Shoreline Court, Suite 300, South San Francisco, United States
PhishTourFunds
PhishTourFunds Jan. 22 at 3:57 PM
$VCYT 💪
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 12:51 PM
$VCYT RSI: 46.39, MACD: -0.1985 Vol: 1.08, MA20: 42.87, MA50: 43.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 30 at 3:38 AM
$VCYT Pullback from $50 mostly complete (weekly chart has several “air gaps”) and accumulation well underway
0 · Reply
EfficiencyExpert
EfficiencyExpert Dec. 26 at 10:12 AM
$VCYT Macro trends are relevant, yet internal execution remains the decisive catalyst. Sequential performance needs to stabilize convincingly. Momentum stabilizes only when delivery becomes predictable. The outlook strengthens only as evidence accumulates.
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 7:37 PM
$VCYT's Afirma is outperforming, but is macro pressure a threat? 🤔 📈 Afirma's 13% volume growth and Decipher's 14th consecutive quarter of >25% YoY growth highlight strong diagnostics demand. ⚠️ Macro challenges led to an 11.6% rise in total cost of revenues, impacting growth. Discover the full story on VCYT here 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-body-26098&ADID=SYND_STOCKTWITS_TWEET_2_2808193_BODY_26098
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 6:37 PM
Is $VCYT finally a buy — or a value trap in disguise? ⚖️ Afirma and Decipher are driving strong test volume growth and the company sports a debt-free balance sheet, but rising macro costs and expenses are clearly tempering the outlook. Get the full risk/reward breakdown before making a move 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-teaser-26097&ADID=SYND_STOCKTWITS_TWEET_2_2808193_TEASER_26097
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 22 at 12:55 PM
$VCYT 🔥
0 · Reply
Estimize
Estimize Dec. 18 at 12:09 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 8:11 PM
$VCYT Current Stock Price: $43.12 Contracts to trade: $45 VCYT Dec 19 2025 Call Entry: $0.40 Exit: $0.76 ROI: 89% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Dec. 2 at 9:00 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
Latest News on VCYT
Veracyte: Profitable, De-Risked, And Ready To Run

Jan 16, 2026, 9:44 AM EST - 14 days ago

Veracyte: Profitable, De-Risked, And Ready To Run

Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 3:16 PM EST - 15 days ago

Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Jan 11, 2026, 4:30 PM EST - 19 days ago

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 4:30 PM EST - 4 weeks ago

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Veracyte to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:30 AM EST - 3 months ago

Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 11:46 PM EST - 3 months ago

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript

Veracyte Announces Third Quarter 2025 Financial Results

Nov 4, 2025, 4:05 PM EST - 3 months ago

Veracyte Announces Third Quarter 2025 Financial Results

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Nov 3, 2025, 4:15 PM EST - 3 months ago

Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Oct 15, 2025, 5:31 PM EDT - 3 months ago

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Sep 28, 2025, 4:00 PM EDT - 4 months ago

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Sep 24, 2025, 9:00 AM EDT - 4 months ago

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 10:31 PM EDT - 5 months ago

Veracyte, Inc. (VCYT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Sep 9, 2025, 9:00 AM EDT - 5 months ago

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 29, 2025, 8:30 AM EDT - 5 months ago

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Aug 27, 2025, 11:25 AM EDT - 5 months ago

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Aug 26, 2025, 10:18 AM EDT - 5 months ago

Veracyte: Q2 Earnings Brings My Position Out Of Mothballs

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Aug 26, 2025, 8:30 AM EDT - 5 months ago

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 2:20 AM EDT - 6 months ago

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Veracyte Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Veracyte Announces Second Quarter 2025 Financial Results

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 17, 2025, 5:30 PM EDT - 7 months ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Jul 8, 2025, 4:05 PM EDT - 7 months ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 28, 2025, 4:05 PM EDT - 8 months ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 8, 2025, 12:49 AM EDT - 9 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

Veracyte Announces First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 9 months ago

Veracyte Announces First Quarter 2025 Financial Results

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 25, 2025, 7:00 AM EDT - 10 months ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 22, 2025, 9:00 AM EDT - 10 months ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Apr 21, 2025, 4:05 PM EDT - 10 months ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 25, 2025, 4:05 PM EDT - 11 months ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Mar 19, 2025, 5:00 PM EDT - 11 months ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:32 AM EST - 1 year ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 25, 2025, 10:16 AM EST - 1 year ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 10:53 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:05 PM EST - 1 year ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 14, 2025, 8:30 AM EST - 1 year ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 11, 2025, 8:30 AM EST - 1 year ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 5, 2025, 8:30 AM EST - 1 year ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Feb 4, 2025, 4:30 PM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Dec 5, 2024, 4:05 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:49 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Veracyte Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Third Quarter 2024 Financial Results

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Oct 16, 2024, 6:43 PM EDT - 1 year ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 7, 2024, 2:08 PM EDT - 1 year ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:17 PM EDT - 1 year ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Veracyte Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jul 17, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

PhishTourFunds
PhishTourFunds Jan. 22 at 3:57 PM
$VCYT 💪
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 20 at 12:51 PM
$VCYT RSI: 46.39, MACD: -0.1985 Vol: 1.08, MA20: 42.87, MA50: 43.30 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 30 at 3:38 AM
$VCYT Pullback from $50 mostly complete (weekly chart has several “air gaps”) and accumulation well underway
0 · Reply
EfficiencyExpert
EfficiencyExpert Dec. 26 at 10:12 AM
$VCYT Macro trends are relevant, yet internal execution remains the decisive catalyst. Sequential performance needs to stabilize convincingly. Momentum stabilizes only when delivery becomes predictable. The outlook strengthens only as evidence accumulates.
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 7:37 PM
$VCYT's Afirma is outperforming, but is macro pressure a threat? 🤔 📈 Afirma's 13% volume growth and Decipher's 14th consecutive quarter of >25% YoY growth highlight strong diagnostics demand. ⚠️ Macro challenges led to an 11.6% rise in total cost of revenues, impacting growth. Discover the full story on VCYT here 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-body-26098&ADID=SYND_STOCKTWITS_TWEET_2_2808193_BODY_26098
0 · Reply
ZacksResearch
ZacksResearch Dec. 23 at 6:37 PM
Is $VCYT finally a buy — or a value trap in disguise? ⚖️ Afirma and Decipher are driving strong test volume growth and the company sports a debt-free balance sheet, but rising macro costs and expenses are clearly tempering the outlook. Get the full risk/reward breakdown before making a move 👉 https://www.zacks.com/stock/news/2808193/is-this-the-right-time-to-add-veracyte-stock-to-your-portfolio?cid=sm-stocktwits-2-2808193-teaser-26097&ADID=SYND_STOCKTWITS_TWEET_2_2808193_TEASER_26097
0 · Reply
PhishTourFunds
PhishTourFunds Dec. 22 at 12:55 PM
$VCYT 🔥
0 · Reply
Estimize
Estimize Dec. 18 at 12:09 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 10 at 8:11 PM
$VCYT Current Stock Price: $43.12 Contracts to trade: $45 VCYT Dec 19 2025 Call Entry: $0.40 Exit: $0.76 ROI: 89% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Estimize
Estimize Dec. 2 at 9:00 PM
Wall St is expecting 0.39 EPS for $VCYT Q4 [Reporting 03/02 AMC] http://www.estimize.com/intro/vcyt?chart=historical&metric_name=eps&utm_co
0 · Reply
JarvisFlow
JarvisFlow Dec. 2 at 6:02 PM
Morgan Stanley has updated their rating for Veracyte ( $VCYT ) to Underweight with a price target of 48.
0 · Reply
SilverEagle
SilverEagle Dec. 2 at 2:05 PM
$VCYT let it ride
0 · Reply
PhishTourFunds
PhishTourFunds Nov. 24 at 5:40 PM
$VCYT Back at it 🔥
0 · Reply
VincM
VincM Nov. 20 at 7:32 PM
$VCYT wants higher
0 · Reply
VincM
VincM Nov. 20 at 6:20 PM
$VCYT trying to break up
0 · Reply
JarvisFlow
JarvisFlow Nov. 11 at 4:59 PM
Morgan Stanley has adjusted their stance on Veracyte ( $VCYT ), setting the rating to Underweight with a target price of 28 → 40.
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 1:24 PM
$VCYT just crushed Q3 earnings — why this stock is soaring! 🚀 📈 EPS jumped 54.5% from the year-ago period, beating estimates by 59.4% 💰 Q3 revenue up 13.8% year over year, outpacing forecasts by 5.5% 🔝 Shares soared 27.5% post-earnings Find out what’s driving this breakout 👉 https://www.zacks.com/stock/news/2789079/vcyt-stock-gains-on-q3-earnings-and-revenue-beat-25-view-up?cid=sm-stocktwits-2-2789079-body-20394&ADID=SYND_STOCKTWITS_TWEET_2_2789079_BODY_20394
0 · Reply
ZacksResearch
ZacksResearch Nov. 11 at 12:24 PM
$VCYT surges after crushing Q3 expectations — is this just the start? 🚀 Earnings and revenue both beat estimates, fueled by strong growth in Decipher and Afirma test volumes. Full breakdown of Veracyte’s Q3 momentum and upgraded 2025 outlook here 👉 https://www.zacks.com/stock/news/2789079/vcyt-stock-gains-on-q3-earnings-and-revenue-beat-25-view-up?cid=sm-stocktwits-2-2789079-teaser-20393&ADID=SYND_STOCKTWITS_TWEET_2_2789079_TEASER_20393
0 · Reply